Production (Stage)
Mineralys Therapeutics, Inc.
MLYS
$16.12
$0.503.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.78M | 23.82M | 20.65M | 18.30M | 16.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 201.49M | 192.40M | 168.35M | 134.51M | 105.08M |
| Operating Income | -201.49M | -192.40M | -168.35M | -134.51M | -105.08M |
| Income Before Tax | -188.51M | -177.81M | -153.25M | -119.67M | -90.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -188.51 | -177.81 | -153.25 | -119.67 | -90.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -188.51M | -177.81M | -153.25M | -119.67M | -90.80M |
| EBIT | -201.49M | -192.40M | -168.35M | -134.51M | -105.08M |
| EBITDA | -201.44M | -192.36M | -140.61M | -80.51M | -35.35M |
| EPS Basic | -3.74 | -3.64 | -3.27 | -2.71 | -2.19 |
| Normalized Basic EPS | -2.33 | -2.28 | -2.05 | -1.69 | -1.37 |
| EPS Diluted | -3.74 | -3.64 | -3.27 | -2.71 | -2.19 |
| Normalized Diluted EPS | -2.33 | -2.28 | -2.05 | -1.69 | -1.37 |
| Average Basic Shares Outstanding | 202.29M | 194.03M | 184.17M | 174.28M | 164.68M |
| Average Diluted Shares Outstanding | 202.29M | 194.03M | 184.17M | 174.28M | 164.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |